Structure Therapeutics Inc.
GPCRNext catalyst
ACCG-2671
Obesity
Get an email about GPCR's next catalysts
Track Structure Therapeutics (GPCR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
GPCR Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.51 | FQ end Sep/2026 | Call: tbd
ACCG-2671 Phase 2 Est. Readout
Estimated primary completion for ACCG-2671 trial (NCT07815678) in Obesity. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Aleniglipron
Obesity, Overweight, or Chronic Weight Management
GSBR-1290
Overweight or Obesity
ACCG-2671
Obesity
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Aleniglipron | Phase 3 | Obesity, Overweight, or Chronic Weight Management | - | - |
GSBR-1290 | Phase 2 | Overweight or Obesity | - | - |
ACCG-2671 | Phase 2 | Obesity | - | - |
Frequently asked questions
What is in Structure Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Structure Therapeutics Inc.'s (GPCR) pipeline across Phase 3, Phase 2. Its lead program is Aleniglipron (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Structure Therapeutics Inc.'s next FDA catalyst?→
Structure Therapeutics Inc.'s (GPCR) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GPCR biotech catalysts?→
Add GPCR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Structure Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.